Beiley Biofund

Beiley Biofund is an early-stage venture capital firm dedicated to promoting life sciences through partnerships with innovators to develop breakthrough cures and technology. The firm focuses on investing in companies that address high unmet medical needs, aiming to advance healthcare solutions through strategic collaborations.

The firm's investment strategy centers on identifying and supporting early-stage companies in the biotechnology and healthcare sectors. Beiley Biofund typically engages in seed and Series A funding rounds, providing capital to startups that demonstrate innovative approaches to medical challenges. The firm operates primarily in the United States and Taiwan, reflecting its commitment to fostering international partnerships in the life sciences industry.

Beiley Biofund's portfolio includes investments in companies like VerImmune Inc., a biotechnology firm developing a Virus-inspired Particle (ViP™) platform technology. In September 2024, Beiley Biofund led a $4.5 million first closing of VerImmune's Pre-Series A financing round, highlighting its active role in supporting promising biotech ventures. This investment underscores Beiley Biofund's philosophy of backing companies with the potential to revolutionize healthcare through innovative solutions.